{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T21:42:41Z","timestamp":1770327761304,"version":"3.49.0"},"reference-count":29,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T00:00:00Z","timestamp":1709337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diseases"],"abstract":"<jats:p>Introduction: Beta-lactamases are frequently prescribed for Gram-negative bloodstream infections (BSIs). However, chromosomally encoded AmpC-producing Enterobacterales (AE) could overproduce beta-lactamases when exposed to third-generation cephalosporins (3GCs), with a risk of clinical failure. There are few available in vivo data on the subject. Our goal was to assess the potential role of AE as a predictive factor for clinical failure in patients with BSIs. Materials and Methods: We retrospectively analyzed patients admitted to Cannes hospital between 2021 and 2022 for BSIs due to Enterobacterales. Patient demographics, comorbidities, and main clinical and laboratory parameters during hospitalization were collected. The risk factors for clinical instability after 48 h or death, as well as for ineffective initial empirical therapy, were assessed using univariate and multivariate analyses. Results: From January 2021 to December 2022, 101 subjects were included (mean age 79 years, 60% men, 97% with comorbidities, 17% with healthcare-associated infection, 13% with septic shock, 82% with qPitt severity score &lt; 2, 58% with urinary tract infection, and 18% with AE). Septic shock [adjusted odds ratio (ORadj) = 5.30, 95% confidence interval (CI): 1.47\u201322.19, p = 0.014] and ineffective initial empirical therapy [ORadj 5.54, 95% CI: 1.95\u201317.01, p = 0.002] were independent predictive factors for clinical instability or death. Extended-spectrum beta-lactamases [ORadj 9.40, 95% CI: 1.70\u201362.14, p = 0.012], AE group [ORadj 5.89, 95% CI: 1.70\u201321.40, p = 0.006], and clinical instability or death [ORadj 4.71, 95% CI: 1.44\u201317.08, p = 0.012] were independently associated with ineffective empirical therapy. Conclusions: Infection with AE was associated with treatment failure. Empirical therapy may result in failure if restricted to 3GC.<\/jats:p>","DOI":"10.3390\/diseases12030052","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T08:03:47Z","timestamp":1709539427000},"page":"52","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Wild-Type AmpC Beta-Lactamase-Producing Enterobacterales Are a Risk Factor for Empirical Treatment Failure in Patients with Bloodstream Infection"],"prefix":"10.3390","volume":"12","author":[{"given":"Matteo","family":"Vassallo","sequence":"first","affiliation":[{"name":"Department of Internal Medicine\/Infectious Diseases, Cannes General Hospital, 06400 Cannes, France"},{"name":"Unit\u00e9 de Recherche Clinique Cote d\u2019Azur (UR2CA), URRIS, Centre Hospitalier Universitaire, Pasteur 2, 06000 Nice, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5670-1322","authenticated-orcid":false,"given":"Roxane","family":"Fabre","sequence":"additional","affiliation":[{"name":"Public Health Department, Archet Hospital, Nice University, 06202 Nice, France"},{"name":"Pain Department and FHU InovPain, Nice University Hospital, Cote Azur University, 06000 Nice, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurene","family":"Lotte","sequence":"additional","affiliation":[{"name":"Multipurpose Laboratory, Bacteriology and Virology Unit, Cannes General Hospital, 06400 Cannes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Manni","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine\/Infectious Diseases, Cannes General Hospital, 06400 Cannes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Pradier","sequence":"additional","affiliation":[{"name":"Public Health Department, Archet Hospital, Nice University, 06202 Nice, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,2]]},"reference":[{"key":"ref_1","unstructured":"(2023, November 25). Antimicrobial Resistance and the United Nations Sustainable Development Cooperation Framework: Guidance for United Nations Country Teams. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240036024."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1080\/21505594.2016.1152440","article-title":"Bloodstream Infections: The peak of the iceberg","volume":"7","author":"Viscoli","year":"2016","journal-title":"Virulence"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"105834","DOI":"10.1016\/j.ijantimicag.2019.10.015","article-title":"Infections caused by naturally AmpC-producing Enterobacterales: Can we use third-generation cephalosporins? A narrative review","volume":"55","author":"Mizrahi","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ijantimicag.2012.06.004","article-title":"Antibiotic therapy for inducible AmpC \u03b2-lactamase-producing Gram-negative bacilli: What are the alternatives to carbapenems, quinolones and aminoglycosides?","volume":"40","author":"Harris","year":"2012","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10096-018-3186-x","article-title":"Ceftriaxone promotes the emergence of AmpC-overproducing Enterobacteriaceae in gut microbiota from hospitalized patients","volume":"37","author":"Goulenok","year":"2018","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","article-title":"Infectious Diseases Society of America Guidance on the treatment of AmpC \u03b2 Lactamase producing Enterobacterales, Carbapenem resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections","volume":"74","author":"Tamma","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1001\/jama.290.19.2588","article-title":"Comparison of 8 vs. 15 days of antibiotic therapy for ventilator associated pneumonia in adults: A randomized trial","volume":"290","author":"Chastre","year":"2003","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"106809","DOI":"10.1016\/j.ijantimicag.2023.106809","article-title":"Effectiveness of third-generation cephalosporins or piperacillin compared with cefepime or carbapenems for severe infections caused by wild-type AmpC \u03b2-lactamase-producing Enterobacterales: A multi-centre retrospective propensity-weighted study","volume":"62","author":"Maillard","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13613-022-01079-5","article-title":"Clinical outcome of wild-type AmpC-producing Enterobacterales infection in critically ill patients treated with \u03b2-lactams: A prospective multicenter study","volume":"12","author":"Mounier","year":"2022","journal-title":"Ann. Intensiv. Care"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s15010-019-01277-7","article-title":"Derivation of a quick Pitt bacteremia score to predict mortality in patients with Gram-negative bloodstream infection","volume":"47","author":"Battle","year":"2019","journal-title":"Infection"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1086\/423382","article-title":"Bloodstream infections caused by Enterobacter species: Predictors of 30-day mortality rate and impact of broad-spectrum cephalosporin resistance on outcome","volume":"39","author":"Kang","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2147\/OAEM.S69974","article-title":"Acute care of older patients in the emergency department: Strategies to improve patient outcomes","volume":"7","author":"Kennelly","year":"2015","journal-title":"Open Access Emerg. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/fampra\/cmh212","article-title":"Six month outcomes after emergency admission of elderly patients to a community or a district general hospital","volume":"21","author":"Round","year":"2004","journal-title":"Fam. Pr."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1111\/j.1532-5415.2007.01400.x","article-title":"The geriatric emergency department","volume":"55","author":"Hwang","year":"2007","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Neyer, G., Andersson, G., Kulu, H., Bernardi, L., and B\u00fchler, C. (2013). The Demography of Europe, Springer.","DOI":"10.1007\/978-90-481-8978-6"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.5492\/wjccm.v1.i1.23","article-title":"Severe sepsis and septic shock in the elderly: An overview","volume":"1","author":"Juneja","year":"2012","journal-title":"World J. Crit. Care Med."},{"key":"ref_17","first-page":"20","article-title":"Sepsis and Immunosenescence in the Elderly Patient: A Review","volume":"4","author":"Aldecoa","year":"2017","journal-title":"Front. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000324008","article-title":"Virulence factors of gram-negative bacteria in sepsis with a focus on Neisseria meningitides","volume":"17","author":"Livorsi","year":"2011","journal-title":"Contrib. Microbiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jgar.2021.03.019","article-title":"Long-term outcome and risk factors for late mortality in Gram-negative bacteraemia: A retrospective cohort study","volume":"25","author":"Baltas","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Breijyeh, Z., Jubeh, B., and Karaman, R. (2020). Resistance of Gram-Negative Bacteria to Current Antibacterial Agents and Approaches to Resolve It. Molecules, 25.","DOI":"10.3390\/molecules25061340"},{"key":"ref_21","unstructured":"Lemenand, O., Caillon, J., Coeffic, T., Colomb-Cotinat, M., Thibaut, S., and Birgand, G. (2023, December 07). National Primary Care Surveillance of Resistance to 3rd-Generation Cephalosporins and Fluoroquinolones in Urinary Isolates of Escherichia coli: 2015\u20132019 Trends in France. Article\u2014Bulletin Epid\u00e9miologique Hebdomadaire. Available online: www.santepubliquefrance.fr."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.jinf.2021.09.016","article-title":"Decreasing proportion of extended-spectrum beta-lactamase among E. coli infections during the COVID-19 pandemic in France","volume":"83","author":"Lemenand","year":"2021","journal-title":"J. Infect."},{"key":"ref_23","unstructured":"(2023, December 01). Antimicrobial Resistance Surveillance in Europe 2022\u20132020 Data. Available online: https:\/\/www.ecdc.europa.eu\/en\/publications-data\/antimicrobial-resistance-surveillance-europe-2022-2020-data."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1086\/666331","article-title":"Association between vancomycin-resistant Enterococci bacteremia and ceftriaxone usage","volume":"33","author":"McKinnell","year":"2012","journal-title":"Infect. Control. Hosp. Epidemiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10096-023-04715-5","article-title":"Cefepime versus carbapenems for treatment of AmpC beta-lactamase-producing Enterobacterales bloodstream infections","volume":"43","author":"Herrmann","year":"2023","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1128\/CMR.05041-11","article-title":"Combination therapy for treatment of infections with gram-negative bacteria","volume":"25","author":"Tamma","year":"2012","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e1063","DOI":"10.1097\/CCM.0000000000005337","article-title":"Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock","volume":"49","author":"Evans","year":"2021","journal-title":"Crit. Care Med."},{"key":"ref_28","first-page":"CD003344","article-title":"Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis","volume":"2014","author":"Paul","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1128\/AAC.01083-07","article-title":"Emergence of Antibiotic Resistance during Therapy for Infections Caused by Enterobacteriaceae Producing AmpC \u03b2-Lactamase: Implications for Antibiotic Use","volume":"52","author":"Choi","year":"2008","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-9721\/12\/3\/52\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:08:22Z","timestamp":1760105302000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-9721\/12\/3\/52"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,2]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["diseases12030052"],"URL":"https:\/\/doi.org\/10.3390\/diseases12030052","relation":{},"ISSN":["2079-9721"],"issn-type":[{"value":"2079-9721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,2]]}}}